Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 6NIH 5INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

CNS 3

Conditions

Carcinoma, Non-Small-Cell Lung 927Neoplasms 612Breast Neoplasms 611Colorectal Neoplasms 458Neoplasm Metastasis 398Ovarian Neoplasms 333Prostatic Neoplasms 316Melanoma 316Lung Neoplasms 294Multiple Myeloma 293Recurrence 281Squamous Cell Carcinoma of Head and Neck 248Stomach Neoplasms 232Pancreatic Neoplasms 231Leukemia, Myeloid, Acute 224Triple Negative Breast Neoplasms 193Endometrial Neoplasms 190Carcinoma, Renal Cell 183Lymphoma, Non-Hodgkin 178Carcinoma, Hepatocellular 178Small Cell Lung Carcinoma 166Leukemia, Lymphocytic, Chronic, B-Cell 158Advanced Solid Tumors 158Lymphoma, Follicular 150Lymphoma, Large B-Cell, Diffuse 141Urinary Bladder Neoplasms 140Lymphoma 138Advanced Solid Tumor 137Uterine Cervical Neoplasms 136Head and Neck Neoplasms 134

Interventions

mirdametinib 1Mn-PyC3A 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neurofibroma × 1 year × Clear all
NCT03962543 2026-05-06

ReNeu

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 2 Active not recruiting
114 enrolled 25 charts 1 FDA
CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Reveal Pharmaceuticals Inc.

Phase 2 Completed
18 enrolled
CNS

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

NCT05891847 2025-06-10

Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

AstraZeneca

Active not recruiting
150 enrolled
CNS

Neurofibroma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡